The Global Market for Hormone Replacement Therapy (HRT) is Projected to Reach US$3.5 Billion by 2022

Increasing Population of Menopausal Women Drives Hormone Replacement Therapy Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Hormone Replacement Therapy (HRT) market. The global market for Hormone Replacement Therapy (HRT) is projected to reach US$3.5 billion by 2022, driven by increasing population of postmenopausal women and growing awareness on menopausal symptoms and available therapies.

Hormone replacement therapy (HRT), also known as ERT (Estrogen Replacement Therapy), refers to administration of estrogen hormones to female patients for replenishing declining natural hormone levels due to menopause. Women in the menopausal phase face several debilitating symptoms due to the change in hormonal levels. HRT includes administration of synthetic and natural estrogens, either alone of supplemented with progesterone, for alleviating various menopausal symptoms, called vasomotor symptoms, such as vaginal dryness, hot flashes (or hot flushes), sleep disturbances, and night sweats. The HRT market is currently in a state of flux, typified by high levels of distrust among target population over safety and efficacy incited by slew of studies highlighting the adverse events that could result from using HRT. Different studies and guidelines providing differing views on the efficacy and safety of various hormone replacement therapies are causing confusion among prescribers and patients.

Despite the confusion, controversies and competition prevailing in the market, the global market continues to record positive growth, driven by factors such as increasing number of menopausal women and growing awareness among women on symptoms and availability of therapies. Development of drugs with novel delivery systems such as transdermal estrogen and vaginal estrogen products, and increasing focus on low-dose HRT against the backdrop of growing research support for low dose drugs for better safety are also driving demand. Increasing sales of approved bioidentical therapies, failure of the non-hormonal therapy segment to demonstrate better efficacy over HRT, sustenance of HRT as the most effective treatment option and regulatory controls over unapproved bioidentical and custom compounded drugs are expected to drive growth in the market in the coming years. The continuing controversy over HRT related to various adverse effects remains a major deterrent to its adoption. Cost of drugs is another market restraint, with substantially higher costs of approved products making them unaffordable for a large section of the patient population, particularly in developing markets. Growing reliance in unapproved compounding pharmacy products, particularly in developed markets such as the U.S. and Europe, and increased penetration of generics are other major bottlenecks to growth.

As stated by the new market research report on Hormone Replacement Therapy (HRT), the United States represents the largest market worldwide, supported by higher awareness of menopause symptoms, easy availability of advanced medications, and higher affordability of expensive medications. Asia-Pacific ranks as the fastest growing market worldwide, with a CAGR of 6.7% through the analysis period, driven by changing perspectives about menopause and increased willingness to seek treatment to manage menopausal symptoms.

Major players covered in the report include Abbott Laboratories, AbbVie, Inc., Allergan plc, Bayer Pharma AG, Hisamitsu Pharmaceutical Co., Inc., Noven Pharmaceuticals, Inc., Novartis AG, Novo Nordisk A/S, Orion Pharma AB, Pfizer, Inc., Rottapharm Madaus, Teva Pharmaceutical Industries Ltd. and TherapeuticsMD, Inc. among others.

The research report titled “Hormone Replacement Therapy (HRT): A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for Hormone Replacement Therapy (HRT) in terms of US$ for all major geographic markets such as the US, Canada, Europe (France, Germany, Italy, UK, Spain and Rest of Europe) Asia-Pacific, Latin America and Rest of World.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.